References
- McClellan KJ, Jarvis B. Lercanidipine: A review of its use in hypertension. Drugs 2000;60:1123–1140.
- Charde S, Kumar L, Saha R. Development and validation of high-performance liquid chromatographic method for estimation of lercanidipine in rabbit serum. Anal Letters 2007;40:2128–2140.
- Bianchi G, Passoni A, Griffini PL. Effects of a new calcium antagonist, Rec 15/2375, on cardiac contractility of conscious rabbits. Pharmacol Res 1989;21:193–200.
- Bang LM, Chapman TM, Goa KL. Lercanidipine: A review of its efficacy in the management of hypertension. Adis Drug Evaluation 2003;65:1123–1140.
- Alvarez-Lueje A, Pujol S, Squella JA, Núñez-Vergara LJ. A selective HPLC method for determination of lercanidipine in tablets. J Pharm Biomed Anal 2003;31:1–9.
- Herbette LG, Vecchiarelli M, Sartani A, Leonardi A. Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press Suppl 1998;2:10–17.
- Krzesinski JM. [Pharma-clinics. Drug of the month. Lercanidipine (Zanidip)]. Rev Med Liege 1999;54:832–834.
- Christians T, Diewald D, Wessler C, Otte Y, Lehmann J, Holzgrabe U. Resolution of newly synthesized racemic dihydropyridines with different chiral selectors by means of capillary electrophoresis. J Chromatogr A 1999;853:455–460.
- Christians T, Holzgrabe U. Enantioseparation of dihydropyridine derivatives by means of neutral and negatively charged β-cyclodextrin derivatives using capillary electrophoresis. Electrophoresis 2000;21:3609–3617.
- Barchielli M, Dolfini E, Farina P. Clinical pharmacokinetics of lercanidipine. J Cardiovasc Pharmacol 1997;29:1–15.
- Jabor VA, Coelho EB, Ifa DR, Bonato PS, dos Santos NA, Lanchote VL. Enantioselective determination of lercanidipine in human plasma for pharmacokinetic studies by normal-phase liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003;796:429–437.
- Stability testing of new drug substances and products. ICH Expert Working Group. Available at: http://www.ich.org/LOB/media/MEDIA419.pdf. Accessed on 2nd November 2007.
- ICH-Q1A (R2), stability testing of new substances and products. International Conference on Harmonization, Geneva. 2003. http://www.ich.org/cache/compo/363-272-j.htm-Q1A (R2).
- Reynolds DW, Facchine KL, Mullaney JF, Alsante KM, Hatajik TD, Motto MG. Available guidance and best practices for conducting forced degradation studies. Pharm Technol 2002;26:48–56.
- Bakshi M, Singh S. Development of validated stability-indicating assay methods–critical review. J Pharm Biomed Anal 2002;28:1011–1040.
- Zumdahl SS. Chemistry. Lexington, MA: Houghton Mifflin Company, 1993;3:645.
- Lund W, Waaler T. The kinetics of atropine and apoatropine in aqueous solutions. Acta Chem Scand 1968;22:3085–3097.
- Mayer W, Erbe S, Wolf G, Voigt R. [The analysis and stability of various 1,4-benzodiazepines of pharmaceutical interest. 2. Ring contraction of nordiazepam and clonazepam. pH-Dependence of hydrolytic cleavage of diazepam (Faustan) and use of kinetic methods for determination of stability behavior of diazepam in solutions of the ampoules]. Pharmazie 1974;29:700–707.
- Verma RK, Garg S. Compatibility studies between isosorbide mononitrate and selected excipients used in the development of extended release formulations. J Pharm Biomed Anal 2004;35:449–458.